Edgewise Therapeutics, Inc.
US ˙ NasdaqGS ˙ US28036F1057

Introduction

This page provides a comprehensive analysis of the known insider trading history of R Michael Carruthers. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate R Michael Carruthers has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:EWTX / Edgewise Therapeutics, Inc. Chief Financial Officer 86,162
Director 4,939
US:BBI / Brickell Biotech Inc Chief Financial Officer 10,000
US:NVLS / Nivalis Therapeutics, Inc. Interim President / CFO 200,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by R Michael Carruthers. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases EWTX / Edgewise Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in EWTX / Edgewise Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EWTX / Edgewise Therapeutics, Inc. Insider Trades
Insider Sales EWTX / Edgewise Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in EWTX / Edgewise Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-08-12 EWTX Carruthers R Michael 1,428 13.3924 1,428 13.3924 19,124 0 13.3900 -3 -0.02
2025-05-02 EWTX Carruthers R Michael 1,314 16.4542 1,314 16.4542 21,621
2024-09-20 EWTX Carruthers R Michael 46,068 28.5862 46,068 28.5862 1,316,909
2024-09-20 EWTX Carruthers R Michael 4,064 28.5862 4,064 28.5862 116,174
2024-09-20 EWTX Carruthers R Michael 24,960 28.5862 24,960 28.5862 713,512
2024-09-20 EWTX Carruthers R Michael 50,000 28.5477 50,000 28.5477 1,427,385
2024-05-02 EWTX Carruthers R Michael 2,157 18.9100 2,157 18.9100 40,789
2024-01-23 EWTX Carruthers R Michael 90,000 15.7751 90,000 15.7751 1,419,759
2023-05-02 EWTX Carruthers R Michael 1,336 8.9049 1,336 8.9049 11,897

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

EWTX / Edgewise Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by R Michael Carruthers as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-08-14 2025-08-12 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -1,428 86,162 -1.63 13.39 -19,124 1,153,916
2025-08-14 2025-08-12 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 5,781 87,590 7.07
2025-05-07 2025-05-02 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -1,314 81,014 -1.60 16.45 -21,621 1,333,021
2025-05-07 2025-05-01 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 5,209 82,328 6.75
2024-10-16 2024-10-11 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 70,000 76,904 1,013.90 0.71 49,700 54,602
2024-10-08 2024-10-04 4 OKUR OnKure Therapeutics, Inc.
Class A Common Stock
A - Award 4,065 4,939 465.10
2024-10-08 2024-10-04 4 OKUR OnKure Therapeutics, Inc.
Class A Common Stock
A - Award 874 874
2024-09-24 2024-09-20 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -50,000 6,904 -87.87 28.55 -1,427,385 197,093
2024-09-24 2024-09-20 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 50,000 56,904 724.22 1.93 96,500 109,825
2024-09-24 2024-09-20 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -24,960 6,904 -78.33 28.59 -713,512 197,359
2024-09-24 2024-09-20 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -4,064 31,864 -11.31 28.59 -116,174 910,871
2024-09-24 2024-09-20 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -46,068 35,928 -56.18 28.59 -1,316,909 1,027,045
2024-09-24 2024-09-20 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 46,068 81,996 128.22 1.93 88,911 158,252
2024-05-03 2024-05-02 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -2,157 35,230 -5.77 18.91 -40,789 666,199
2024-05-03 2024-05-01 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 5,208 37,387 16.18
2024-01-25 2024-01-23 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -90,000 29,024 -75.62 15.78 -1,419,759 457,857
2024-01-25 2024-01-23 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise X 90,000 119,024 310.09 1.93 173,700 229,716
2023-06-26 2023-06-22 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 10,000 29,024 52.57 0.71 7,100 20,607
2023-05-03 2023-05-02 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
S - Sale -1,336 16,126 -7.65 8.90 -11,897 143,600
2023-05-03 2023-05-01 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 5,208 17,462 42.50
2022-05-25 2022-05-23 4 EWTX Edgewise Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -9,000 207,122 -4.16 0.71 -6,390 147,057
2022-05-25 2022-05-23 4 EWTX Edgewise Therapeutics, Inc.
Common Stock
M - Exercise 9,000 12,000 300.00 0.71 6,390 8,520
2022-05-03 2022-05-01 4 EWTX Edgewise Therapeutics, Inc.
Restricted Stock Units
A - Award 15,625 15,625
2021-08-19 2021-08-17 4 EWTX Edgewise Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 120,000 120,000
2020-03-18 2020-03-16 4 BBI Brickell Biotech, Inc.
Restricted Stock Units
A - Award 10,000 10,000 1.54 15,400 15,400
2017-01-23 2017-01-12 4 NVLS Nivalis Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 200,000 200,000
2016-12-05 2016-12-02 4 NVLS Nivalis Therapeutics, Inc.
Common Stock
P - Purchase 24,000 24,000 2.09 50,256 50,256
2016-09-14 2016-09-12 4 NVLS Nivalis Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 110,000 110,000
2015-09-15 2015-09-11 4 NVLS Nivalis Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 55,400 55,400
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)